The cut of the clot(h): Snake venom fibrinogenases as therapeutic agents

E. E. Gardiner; Robert K. Andrews

doi:10.1111/j.1538-7836.2008.03057.x

The cut of the clot(h): Snake venom fibrinogenases as therapeutic agents

E. E. Gardiner
, Robert K. Andrews^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

15 Citations (Scopus)

Abstract

Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics

Original language	English
Pages (from-to)	1360-1362
Number of pages	3
Journal	Journal of Thrombosis and Haemostasis
Volume	6
Issue number	8
DOIs	https://doi.org/10.1111/j.1538-7836.2008.03057.x
Publication status	Published - Aug 2008
Externally published	Yes

Access to Document

10.1111/j.1538-7836.2008.03057.x

Cite this

@article{aa9f0edf569c47399b4269318303f4f3,

title = "The cut of the clot(h): Snake venom fibrinogenases as therapeutic agents",

abstract = "Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics",

author = "Gardiner, \{E. E.\} and Andrews, \{Robert K.\}",

year = "2008",

month = aug,

doi = "10.1111/j.1538-7836.2008.03057.x",

language = "English",

volume = "6",

pages = "1360--1362",

journal = "Journal of Thrombosis and Haemostasis",

issn = "1538-7933",

publisher = "Elsevier B.V.",

number = "8",

}

TY - JOUR

T1 - The cut of the clot(h)

T2 - Snake venom fibrinogenases as therapeutic agents

AU - Gardiner, E. E.

AU - Andrews, Robert K.

PY - 2008/8

Y1 - 2008/8

N2 - Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics

AB - Recent reports on outcomes of clinical trials assessing Viprinex (Ancrod) in the treatment of ischemic stroke [1,2] highlight the re-emerging interest in snake venom serine proteases as therapeutics. In this issue, Paes Leme and colleagues [3] describe a serine protease, Bothrops protease A (BPA) that selectively targets fibrinogen, illustrating the ongoing development of these agents as anti-thrombotics

UR - https://www.scopus.com/pages/publications/47649090828

U2 - 10.1111/j.1538-7836.2008.03057.x

DO - 10.1111/j.1538-7836.2008.03057.x

M3 - Comment/debate

SN - 1538-7933

VL - 6

SP - 1360

EP - 1362

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

IS - 8

ER -

The cut of the clot(h): Snake venom fibrinogenases as therapeutic agents

Abstract

Access to Document

Other files and links

Fingerprint

Cite this